InflaRx’s (IFRX) “Buy” Rating Reiterated at HC Wainwright

InflaRx (NASDAQ:IFRX)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 418.64% from the stock’s current price.

InflaRx Trading Up 0.2 %

NASDAQ:IFRX traded up $0.00 on Wednesday, hitting $1.54. The company had a trading volume of 34,852 shares, compared to its average volume of 166,307. The stock has a market capitalization of $90.82 million, a price-to-earnings ratio of -1.99 and a beta of 1.57. The firm has a 50 day moving average of $1.49 and a two-hundred day moving average of $1.50. InflaRx has a 52 week low of $1.14 and a 52 week high of $3.08.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.04 million. InflaRx had a negative net margin of 44,046.09% and a negative return on equity of 47.03%. As a group, equities analysts forecast that InflaRx will post -0.98 EPS for the current year.

Hedge Funds Weigh In On InflaRx

An institutional investor recently raised its position in InflaRx stock. Ikarian Capital LLC grew its holdings in shares of InflaRx (NASDAQ:IFRX) by 2.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 704,987 shares of the company’s stock after acquiring an additional 16,383 shares during the period. Ikarian Capital LLC owned about 1.20% of InflaRx worth $1,086,000 as of its most recent SEC filing. Institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.